Good morning, and welcome to the AdvanSix First Quarter 2021 Earnings Conference Call. Please note, this event is being recorded. I would now like to turn the conference over to Adam Kressel, Director of Investor Relations. Please go ahead.

Thank you, Betsey. Good morning and welcome to the AdvanSix’s first quarter 2021 earnings conference call. With me here today are President and CEO, Erin Kane; and Senior Vice President and CFO, Michael Preston. This call and webcast, including any non-GAAP reconciliations are available on our website at investors.advansix.com. Note that elements of this presentation contain forward-looking statements that are based on our best view of the world and of our business as we see it today. Those elements can change and the actual results could differ materially from those projected. And we ask that you consider them in that light. We refer you to the forward-looking statements included in our press release and earnings presentation. In addition, we identify the principal risks and uncertainties that affect our performance in our SEC filings, including our annual report on Form 10-K as further updated in subsequent filings with the SEC. This morning, we'll review our financial results for the first quarter of 2021 and share our outlook for our key product lines and end markets. Finally, we'll leave time for your questions at the end. So with that, I'll turn the call over to AdvanSix's President and CEO, Erin Kane.

Thanks Adam. And good morning, everyone. Thank you for joining us and for your continued interest in AdvanSix. We do hope you also remain healthy and safe. As you saw in our press release, AdvanSix delivered robust first quarter results to start 2021. Our collective organization contributed to generating significantly higher earnings and cash flow in the quarter, reflecting strong execution amid a tightened supply and demand environment, overall. Mike will detail our financials in a moment. But as you can see on the left-hand side of Slide 3, we've highlighted year-over-year variances for some key metrics in the first quarter. I won't mention them all, but you can see the significant improvement in performance, particularly our ability to nearly double our EBITDA compared to last year, which as you'll recall, was largely unaffected by COVID-19 and to generate a $57 million improvement in free cash flow year-over-year. Our first quarter of 2021 EBITDA was the highest we've seen since the first quarter of 2017 and our second highest quarter since then. Importantly, we've captured pricing, achieved sales volume growth, and expanded margins while further reducing leverage levels. Across the Board, it was a terrific start to 2021, and we are looking to continue building on that momentum. Early in the first quarter, we announced the acquisition of certain assets of Commonwealth Industrial Services or CIS, which enabled us to expand our offering to directly supply packaged ammonium sulfate to customers. The acquisition also diversifies and optimizes our offerings to include a spray-grade adjuvant to support crop protection, a fire retardant and installation, as well as other specialty fertilizers and products for industrial use. I'm proud to say that the integration and synergy realization are progressing well ahead of plan and we are excited to extend our industry-leading value chain for ammonium sulfate. As we look ahead, the outlook for our business remains favorable. In nylon, we expect robust customer demand and improved pricing as we execute our portfolio optimization and experience an improved global economic recovery. In chemical intermediate, we're targeting differentiated product growth as we expand production of oximes in Nadone, as well as cultivate our storefront in those chemical marketplaces, while capturing continued pricing favorability in a tight acetone industry supply and demand environment. Agricultural fundamentals are also improving overall with robust planted acres and crop prices at multi-year highs, supporting an expectation for strong bulk and packaged ammonium sulfate customer demand and our plant nutrients business as we enter the heart of the North America growing season. While we are focused on mitigating continued higher raw material input costs, including freight and logistics, our investments in differentiated product growth, coupled with a targeted record year of production output in 2021, are supporting higher earnings and robust cash flow. There is a lot to be excited about. We can't always predict what the markets will do, but we're highly focused on executing what is in our control and remain confident in our ability to create value for our shareholders. We are executing against a focused strategy to deliver strong and sustainable returns over the long-term. As we support continued operational excellence and improving through-cycle profitability, enhancing our portfolio resiliency through differentiated product growth and mix optimization, and being strong and disciplined stewards of capital. With that, I'll turn it over to Mike to discuss the details of the quarter.

Okay, great. Thanks, Erin. And good morning everyone. I'm now on Slide 4, where I'll cover the first quarter financial results. We once again executed very well, as Erin pointed out, with strong volume growth, pricing improvement, margin expansion and robust cash generation. Sales totaled $376 million, that's up about 24% compared to last year. Sales volume in the quarter increased roughly 8% versus the prior year driven by improved end market demand across our product lines. You recall, sales volume had also increased about 8% in the fourth quarter of 2020 year-over-year, so a continuation of the strong trends we've seen exiting the year. Pricing was favorable by 16% comprised of raw material pass-through pricing of 11%, following a net cost increase in benzene and propylene, and market-based pricing of 5%. The improvement in market-based pricing primarily reflects continued strength in chemical intermediates, particularly acetone. EBITDA was $55 million in the quarter, virtually doubling prior year levels. I'll walk through the key year-over-year variances on the next slide. Earnings per share of $0.98 increased $0.67 per share compared to the prior year. In the quarter, we saw lower effective tax rate compared to last year, primarily driven by two items that drove up last year's rate. First, was the tax impact of equity compensation investing. And second, was the federal carryback claim associated with the CARES Act. Lastly, cash flow from operations was robust in the quarter, reaching $57 million, that's up about $37 million compared to last year, primarily due to higher net income and approximately $12 million cash tax refund, as we anticipated partially offset by the unfavorable impact of changes in working capital. CapEx of $14 million was favorable by roughly $20 million year-over-year, reflecting execution against our 2021 capital priorities and following the completion of several high return growth and cost savings investments in the prior year.

Thanks, Mike. I'm now on Slide 7, where we've included pricing and spreads across our product lines. Starting with nylon. We've seen spreads further improving on the back of industry supply constraints and demand improvement with economies recovering around the globe. This quarter we've also shown the resin spread over the upstream benzene input versus comparing to caprolactam costs, which we believe is a better indication of industry performance, particularly for integrated producers like ourselves. Although the industry remains in an oversupplied position globally, we continue to be encouraged by the recent improvement in demand and pricing. The Asia caprolactam to benzene spreads averaged above $900 per ton in the first quarter, the highest level we've seen since the second quarter of 2019, and regionally $1,150 per ton in March. We are monitoring the rise in benzene input costs, which we would expect both caprolactam and resin prices to closely follow moving forward. Overall, nitrogen industry pricing continued to move higher through the first quarter, supported by improving agricultural fundamentals, including crop prices, farmer profitability, and planted acres overall. As a reminder, urea is the largest nitrogen fertilizer by total consumption and tends to have an underlying influence on other nitrogen products. However, ammonium sulfate does have its own supply and demand dynamics, influencing the premium earned for the sulfur nutrient. So while urea pricing did move sharply higher in the quarter, other nitrogen fertilizers, including ammonium sulfate did lag this improvement. In addition, we're tracking significantly higher raw material input costs for the industry. In particular, the Tampa sulfur market recently doubled from last quarter, settling nearly $200 per long ton in the second quarter. That is by far the highest level we've seen since our spinoff in 2016. The recent increase reflects a reduction of supply from lower refinery operating rates fighting the winter storms in the first quarter and expectations of a strong spring ag planting season. Despite this, we expect strong ammonium sulfate performance during the season peak in the second quarter with robust demand and recent price increases. And lastly, industry realized acetone prices over refinery-grade propylene costs continued to expand in the first quarter, amid continued tight supply and demand balance in the U.S., with planned and unplanned downtime impacting industry supply. We've seen the continued expansion of the premium in the small, medium buyer acetone prices over the large broker on a year-over-year basis. As a reminder, the small/medium buyer price is reflective of roughly 1/3 of the domestic industry, where pricing is predominantly freely negotiated. This has come at a time when propylene costs have also continued to surge higher, although have backed off a bit exiting the first quarter. Let's turn to Slide 8 to discuss some industry considerations for 2021. Overall, we are experiencing improved end market conditions across the industries we serve. Many of the key things we discussed last quarter remain in place. We've seen steady carpet mill rates since rebounding from last year’s trough as well as strong residential construction data, particularly with healthy remodeling demand. While our commercial construction continues to lag, which we expect to continue in the near term. We've also seen demand remain resilient into automotive, consumer, and industrial electronics applications. A number of key agriculture indicators continue to trend favorably as well. Lowered expectations for ending stocks, including corn and soybeans have translated into increased crop prices, which have remained at multi-year highs while the profitability outlook for growers continues to improve. Expectations for planted acres overall remain relatively high coupled with nitrogen industry supply tightness coming out of the first quarter and rising input costs have all supported increases in nitrogen pricing. With sulfur demand remaining robust as a key nutrient supporting crop yields, we continue our efforts to drive the sulfur nutrition value proposition down the value chain. Non-acetone is evident that the recovery from the 2018-2019 low has been a positive story for us. We expect a favorable acetone industry supply and demand balance to continue in the near term. Although we'll look for supply availability to increase as we progress through the year with the expected higher phenol industry utilization on the back of improving demand. We're supporting growth across the portfolio through investments in high-value and high-purity applications, as well as in our differentiated nylon products. Our EZ-Blox anti-skinning agent for paints as an example has been gaining traction and is expected to grow roughly 50% in 2021 compared to last year and is an area of targeted CapEx investment for expansion this year. Our nylon efforts remain focused on supporting asset flexibility, new products, application development, and customer qualifications to optimize our mix. We continue to see strong double-digit growth in our wire and cable offerings, while our copolymer sales are expected to double in 2021 versus last year. Let's turn to Slide 9 to wrap up before moving to Q&A. Our strategic priorities and value creation roadmap remain consistent as we support sustainable shareholder return over the long term. First, enhancing our day-to-day execution by strengthening our culture and core foundations of excellence. We are targeting a record year production output in 2021, supporting higher earnings and robust cash flow. We also continue to make meaningful progress on our sustainability initiatives and performance. We are strengthening and empowering a high performing culture supported by our engaged workforce guided always by our core values of safety, integrity, accountability, and respect. We will soon publish our annual sustainability report, which highlights many ongoing initiatives happening around the organization integrated with our overall strategy. I encourage you all to read through it when we publish it. I'm proud to share this week, we were awarded a Platinum Rating for Corporate Social Responsibility by EcoVadis, an independent CSR assessment agency. This follows our Gold Rating in 2020 and ranks us now among the top 1% of all companies assessed. Second, on our core priorities is improving through-cycle profitability by driving superior operational and commercial performance. We're focused on driving improved earnings and cash flow through cost optimization and asset productivity, creating strong operational leverage. We have a number of efforts in place across the organization, targeting improvements in rate, costs, quality, yield, as well as efficiencies in our capital engineering and planned plant turnaround programs. We continue to expect the impact of planned plant turnarounds to be in the range of $25 million to $30 million in 2021, which is a reduction compared to approximately $31 million in 2020 and $35 million in 2019. For maintaining a rigorous focus on productivity and cost savings with approximately half of the 2020 cost savings living through based on structural and permanent actions taken throughout last year. Mostly, we continue to perform well, reflecting the strength of our business model, global low-cost position and diversity of our product portfolio amid a tightened supply and demand environment overall. In addition, we're focused on mitigating expected higher raw material input costs in 2021. Our third priority is enabling sustainable long-term growth by enhancing portfolio resiliency. We've talked more about our differentiated products, which are focused in the areas of high purity applications, high value intermediates, and differentiated nylon. These products represented approximately 12% of our total sales in 2020, an increase from approximately 8% of our sales in 2017. I would note that this does not include our granular ammonium sulfate product, which represents nearly 20% of our total sales last year, and is viewed as high value for the premium it earns. Although building our smaller basis, we've continued to see strong growth across these products. In the first quarter of 2021, sales of these products increased nearly 30% on a year-over-year basis. We are bolstering growth through investments in our Nadone and oximes product lines, serving these high purity and high-value applications while continuing to optimize our nylon offerings. Our final priority is enhancing value creation through disciplined capital stewardship. We have reduced our expected range for CapEx to $70 million to $80 million in 2021. Now that is down about $10 million from higher expectations, reflecting efficiencies in our planning and execution. This year does include spend towards high-return growth and cost savings projects. As you may recall, we originally targeted a $150 million to $200 million pipeline of projects shortly after this spin; that pipeline continues to be robust at $50 million to $100 million with smaller projects from which we continue to refine, prioritize and execute against. We expect leverage to trend near the lower end of our target range by year-end and have approximately $60 million remaining under a share repurchase authorization. As I mentioned earlier in the call, we've also had success inorganically with a recent bolt-on acquisition of CIS, and we'll continue to assess other opportunistic acquisitions that would have strong portfolio coherence with our product lines and technologies. We're leveraging all of the momentum being built as we execute against this focus strategy and continue to strengthen our ability to deliver long-term value for all of our key stakeholders. With that, Adam, let's move to Q&A.

Great. Thanks, Erin. Betsey, could you please open the line for Q&A.

We will now begin the question-and-answer session. Our first question comes from David Silver with CL King. Please go ahead.

Okay. Thank you. Good morning.

Good morning, Dave.

Good morning.

Hey. I wanted to – I have a number of questions here. But maybe if we could just drill down on the LIFO layers issue that cropped up this quarter. So maybe if you could just provide a little background on the genesis or the origination of those LIFO layers, that would be great? And then more to the point, would you anticipate further adjustments in coming quarters? In other words, will you touch on even more of those older LIFO layers going forward? Thanks.

Yes. Well, that's a good question, Dave. Yes, so we are on LIFO accounting, and we did have to make an adjustment of $6.6 million in the quarter, as we communicated as a result of a reduction in inventories from 2020. We saw the reduction in the quarter, and simply what that means is you need to go back to prior year layers and evaluate the cost of those layers. Some of those layers were at roughly a 20% higher cost in our current standard costs. And as a result, you have to absorb that into the P&L as you reduce the inventory levels. Now going forward, we don't anticipate inventory changes through the year by year-end to change a whole lot for where we are today. So we don't anticipate another adjustment going forward. But we'll obviously continue to monitor our inventory as we go forward here.

Okay. Thank you for that. I next had a question, I guess, on the sales trend this quarter in ammonium sulfate. So when I do the math, the percentage of sales that's allocated to them and your total revenues, it seems like it was a very modest increase year-over-year in ammonium sulfate revenue. And actually, it was a decline from the fourth quarter. So I know there's certainly price and volume and a whole bunch of arms and legs there. But I confess thinking about how the market has improved both demand and price-wise. I confess I'm a little curious why the year-over-year increase was so modest relatively speaking in a market that seems to be quite robust right now? Thank you.

I know in that and certainly we have as we communicated here at David, good expectations for the peak of the season here in Q2. If you think about sort of how you progress throughout the year, the ag cycle runs sort of July to June high in North America. In the fall, there is prep for some fall applications in North America; but then leading to basically building inventory levels for the spring plus the second half also has the contribution of us selling export into South America, as we sort of bridge the two growing seasons as we're producing ammonium sulfates year-round. So it's always difficult to sort of know exactly how that will play out. I think that we are a staging material and selling material into the heart of the season. And again, on a full July to June ag season this will be a stronger season annually versus what we saw last year. So there could be some timing considerations, some mix and Michael if you want to add to it, but I wouldn't reflect it more on a view that we're not going to see the benefits of the strong season coming through in our numbers here in Q2.

Yes, Dave, the only thing I'll add is last year we did have high export standard sales due to some sales timing. We had some shifts of those sales. They can be a little bit lumpy from the fourth quarter of the prior year to the first quarter of last year. We didn't sort of see that repeated the timing this year. So as a result of that timing, that impacted the year-over-year variance. So it's more of a sales timing consideration, really.

Okay. Very good with that. I have a question here on your income tax accrual rate. So it was right around what I expected in the first quarter of 25%, but my assumption is that your earnings – your pre-tax earnings should be significantly higher this year than last year. Sometimes in cases like that, the income tax accrual rate I've found tends to creep up. In other words, there might be a handful of discrete tax benefits that have a certain percentage effect when earnings are at normal levels or slightly below normal. But when earnings ramp up, those discrete benefits kind of fade in importance and as a result, the accrual rate that we should be applying to your pre-tax income kind of can be higher than originally anticipated. So, as your company starts to swing into a higher level of earnings and pre-tax earnings, how should we think about the full year accrual rate for income tax purposes?

No, it’s a good question, Dave. I would – I think still 25% is a good target to assume going forward and we are anticipating higher earnings as we've talked about this year relative to last year. The one thing that we've done a nice job with as we've seen in the past is driving credits and doing a lot of planning to mitigate any of the creep we could see from an effective tax rate. So we continue to push the envelope there. But I still think a 25% sort of target and planning number from an ETR perspective is good. Our cash tax rate will probably be right around the 10% to 15% range that excludes the cash tax refund we got in the first quarter, that's more normalized for the year excluding that. So we continue to see those benefits as well.

Okay. And then maybe one more question and I'll get back in queue. But this would be for Erin and it's a capital deployment question. And with your cash flow generation kind of picking up here and I think with a pretty bright outlook for a couple of quarters, I mean, you're going to have incremental, I guess, flexibility in my opinion. And I'm just wondering, if you could say which there was a little bit of share creep this quarter for instance, but how does the priority for buybacks or the inclination to deploy cash for share repurchases kind of shift here as maybe your flexibility grows? Thanks.

Well, thanks for that, David. And it's certainly consistent with our communications in the past. We are committed to delivering strong and sustainable shareholder returns over the long term and obviously enhancing our value creation through capital allocation is a lever for us and a core strategy. As we drive growth in the business, our allocation priorities has been aligned with one, right as we've already started to demonstrate getting our debt leverage levels into our target range certainly as we had come through 2020 and navigating the pandemic, executing on high return investments in the business. Again, we still have opportunity sets that we continue to refine and prioritize and execute against. These are strong waterline projects for us, right. We're targeting those 20 plus returns type levels. We believe as well that the opportunities we demonstrated with CIS, which for an acquisition is tracking to achieve those levels that we would set for ourselves for capital projects, which is a great opportunity. We'll continue to build out those inorganic pipelines and capabilities. As you note, we recognized that returning excess cash to shareholders is in that mix for us as well. As we progress through the year, we will continue to assess that. We still have our authorization in place. We'll continue to think about what our long-term strategy should be here as well.

Okay. Thank you for that. So, I am going to get back in queue. But I do have a couple more questions for you later. Thank you.

Okay. Right.

Thanks, Dave.

Our next question comes from Vincent Anderson with Stifel. Please go ahead.

Yes, good morning. Great job to start the year off.

Thank you, Vincent. Good morning.

Thank you, Vincent. Good morning.

So let's just start get out of the way, what specifically did you have to deal with in the first quarter from a logistics perspective, particularly with import cumene and export capro? And then how are you positioned into 2Q, both from a cost standpoint and a working capital standpoint?

And maybe if we – the fact we do recognize that we left you all off at our last earnings call in the midst of winter storm and supply chain disruptions. And that sort of that's exactly maybe to get some context there. And then how we see the supply chain stabilizing here through the quarter and into next into Q2. I think certainly the results show that we performed well in a difficult period for the industry. Not that we didn't have any direct physical damage to our facilities, it was really about how do we manage the disruption to the raw material side. There were components of factors, right to the industries in which we participate, plant rates being offline, availability of raw materials led to the transitory sort of tightness in demand, which really the industry is still working through. We were one of the few producers that remained running consistently during that time that certainly supported performance in the quarter. We did take the largest utilization reduction in Frankford and Chesterfield while our Hopewell rates remained relatively strong and consistent with 1Q and 2020 performance. We looked to move things around and protect that value chain. As you know, we did draw down inventories; like know that a significant reduction in the cord that played into the ultimate LIFO consideration, as we worked hard to meet our customer demands and customer needs to support the industry. So, the U.S. demand continues to recover. It has been strong. I think our presence here helped. So, the cumene supply chain is stabilizing back out through Q2, that's our expectation. I think there's still a supply-side tightness. When you think about the height of it, 70% of the phenol acetone supply was off in the U.S., a significant amount of cyclohexanone and others in the capro and nylon chain were impacted. The logistics in the U.S. and the supply side is sorting itself out. When it comes to export considerations, we have to watch that. We do see container ships rolling, availability of containers. We're trying to get ahead by pre-booking where we need to but that is something that certainly we'll continue to monitor. As we continue to see that mix shift back into the U.S., it alleviates a little bit of our exposure on the export levels that perhaps were evident in our 2021, excuse me, 2020 numbers versus what will transpire in 2021.

Yes. Just the only other thing I would add is that if you recall, we started the year in a very good position from an inventory perspective. The cumene and the raw material inventory overall was up $25 million last year and was up $9 million in the fourth quarter and we knew a certain suppliers were going to take plan turnarounds in the first quarter. So that put us in a very good position to weather through some uncertainty in the first quarter as a result of Uri.

Okay, perfect. I appreciate that. And then just thinking about kind of the capital markets outside of the U.S., I just wanted to get a check from your point of view. When we looked at China in the first quarter and kind of just Eastern Asia in general, they had a pretty wild start to the year in terms of gas prices and sulfur over there as well. Do you feel like any of that had contributed to spreads internationally in the first quarter, or was it too short-lived? And what we're seeing right now is just really a good old-fashioned recovery.

There certainly, you may think in Q1, there were supply side disruptions in a number of places around the globe and had them here, Europe, at some point lost nearly 20, 25 or plus percent of its capital oxime capacity with some force majeures. You had your typical sort of – I think ramp ups in China and dislocations potentially of raw material availability too. We've seen some stabilization in Asia as we've come into April, on pricing, on spreads that we're watching. I think there is a quick start to textile demand that has perhaps plateaued a bit here too. We'll be watching that into the second quarter. But I think the greatest, I think opportunity set here are certainly there'll be seen as of late is again, that the demand side has stayed in an improvement trend with recovery, whether it's housing, construction, automotive has posted strong numbers in every region. And as we work through some of these disruptions, I think that will play out as we head forward.

And then I wanted to spend a little bit of time on capital allocation. I know David brought it up, but maybe looking out a little bit further as you become more confident that we're facing a more sustained recovery. First off on the share buyback front, is there a percent of shares outstanding where you think it would make more sense to start curbing repurchases and start thinking about a modest dividend?

May look, first of all, you're aware of what we've done so far from a share repurchase perspective. We've repurchased over $100 million and more than 10% of the company. So, we've done a lot. We still have $60 million remaining on the authorization and we've navigated through more challenging times last year from a leverage perspective and gotten the leverage down quite significantly here down to the bottom in the range. We expect that a farewell trend to continue going forward. So we don't necessarily target specific shares outstanding. I would say as leverage continues to improve, it just gives us more opportunity, more flexibility to create value for shareholders. That could be either through share repurchases or other ways to deploy capital, certainly you bring up dividends. That's something we haven't done yet, but that is something we would continue to evaluate. But also, M&A. I mean, as we get further down in terms of leverage and improve our cash flow generation, we have a very active pipeline; we have opportunities identified in every single one of our product lines. We did our first one this year. There are opportunities out there. We continue to vet and look to deploy capital there as well. It's really across the Board. Again, getting the leverage levels down gives us the opportunity to evaluate those even more robustly going forward.

Kind of headed off a couple of my follow-ups to that, but I'm going to ask them anyways. So, when you think about the debt levels, they are obviously improving drastically. Do you think about maybe – the asset base that you have is in such a strong position operationally, do you think about maybe targeting a lower gross debt level overall to position yourself a little bit better to be opportunistic in a future downturn, or are you just very comfortable with where we are right now?

Again, we've communicated that the range. I mean, certainly we're comfortable we can operate within that range. We have plenty and ample liquidity within our credit facility that we're very, very comfortable with. As we look at opportunities going forward, we’ll again weigh leverage against the outlook for cash flow generation, which we’ve proven we can execute well, and compare that to and consider that as we evaluate all those opportunities for additional value creation. I wouldn't say there's a specific gross debt level we would target; we would look at it in terms of more of a range of leverage ratio. But again, very focused on creating value here.

And then, so to drill into M&A, assuming that we can maintain improving and maybe even getting back to an ideal macro backdrop. Would you expect to prioritize really more incremental downstream add-ons like we've seen so far? Or are you starting to feel more comfortable thinking about expanding the asset base and product mix a bit more significantly?

Yes, when you think about, we've talked before, Vincent, I think when you have one way and historically, we have represented the company in a linear fashion as one value chain as we've been continuing to refine that. We really are much more diverse than just that representation, that in fact we have streams of technologies and chemistries, a wider variety of applications that are in end markets that we are exposed to. Really thinking about the business more diversified into plant nutrients, and software nutrition is an area of continued growth. We’ve got a growing intermediates platform that has continued to perform well. It is getting investment this year, as we think those higher value application sets into coding, the electronic space, whether it's pharma even ag intermediate is a nice franchise that continues to receive growth investments. Areas we think about chemistry either to forward integrate in and around, or expand across the target application sets. Obviously in nylon, we continue to focus organically at the time, right, as we think about that portfolio optimization amid sort of the end market application space. We continue to see strong double-digit growth in our wire and cable offerings, while our copolymer sales are expected to double in 2021 versus last year. So, continue to see us in our disclosures how we represent ourselves into these three, sort of main segments from that standpoint. Well, it's not reportable, really how we are operating and driving discrete strategies around them and where those targeted growth areas could be. So that's been our focus.

No, it makes perfect sense. I appreciate it. And then so I'll just finish up with a couple more focused M&A questions, then kind of tying into exactly what the strategy sounds like. So first, when I think about the nitrogen imbalance in Brazil, they're restarting some urea capacity and then as capro utilization rates kind of tick higher with demand overseas, maybe a little bit more incremental ammonium sulfate competition there specifically. Are there any acquisition opportunities, like the one that you just did here in the U.S. that could help firm up your footprint in that country?

Yes, I mean, just in general, the framework here, there are very few sort of independent players in a space where we sit today, right. Brazil is a large importer of its raw material ag considerations. Again, I will leave my remarks to say that we're exploring all these avenues. We're looking for portfolio coherence, how we continue to – we can increase our margins, we can dampen cyclicality, right. There are traits that we're looking to address both with our organic and inorganic investments in the business. We can go in a number of avenues accordingly with that.

And last one, this one comes from a place of maybe a little bit more ignorance on the acetone side. But just given how tight it has become in the U.S., I know you've always felt really good about the mix and quality of the different grades that you offer. But is there a potential that any of your end users may be struggling in this price environment and present an opportunity to go downstream there?

The end markets in which the acetone goes into are all very robust. I think it’s evidenced by the demand. You've got large BPA consumers, you've got folks who are making methyl methacrylate, all of which are benefiting from, end consumer demands here. You've got strengthening in paints and coatings, and you can look down that value chain of how those end customers are doing. Right now, certainly there are pressures here on pricing. Again, as we noted, we would expect supply availability to ease throughout the year. Certainly, there are about 12K T of imports that have arrived this month. We need imports to help balance out the marketplace. The strength of that value chain right now is rather robust given the end market demands and considerations.

All right. Excellent. Thanks.

Our last question comes from David Silver with CL King. Please go ahead.

Okay, thanks a lot. I think I have kind of a question about the turnaround activity for your company, kind of a two-part question. But could we get an update? I believe, in the second quarter, you scheduled for one of your major pieces of equipment, sulfuric acid, to undergo its annual turnaround. And first of all, I'm just wondering if you could kind of update us on the progress there? And then secondly, I mean, kind of somewhat related, but should I assume that there won't be any interruption or any reduction in your planned shipment capability during the second quarter? In other words, I see the inventory levels coming in to the second quarter. There's a certain amount of production you'll be able to do before you have to take equipment offline. But based on your product availability, and also the timing and execution of the turnarounds, could you just give us an update on how that aspect of your overall operations is progressing through what I consider the peak spring selling season for some of your products? Thanks.

No, I'm happy to David. On a positive note, if we think about the full year impact of turnarounds, continuing to expect $25 million to $30 million. If you look at that on a comparable consideration for likely the same type of turnaround we took, it would be in 2019 at $35 million. I think we continue to focus on our execution and delivery of our turnarounds and creating value here. If you may recall, we take two outages in the year and Hopewell to do one in the spring and one in the fall, one is smaller in the spring. In this case, our turnaround for the sulfuric acid plant will be in the fourth quarter. If you think about that consideration, in the second quarter, we are taking more of our lighter turnaround in Hopewell. We also have the remainder of our Frankfurt turnaround to complete. We did pull as much as we could forward in Q1 as we were navigating the impacts of the winter storm. But we still have some work that has to be completed in the second quarter. We've planned well for these. I think that's shown in the targeted expectations for impact. We continue to drive forward, not just in that execution now in the second quarter, but also in a strong position for good execution as well on the said plant. So again, from a full year perspective, and even in the height of Q2, we think we're still very well positioned. We've moved material into the value chain, into warehouses for the peak of the ammonium sulfate season, as you asked about that specifically.

Okay, thanks. I had one question, I guess, about the engineering resins part of your nylon business. I was listening to a conference call from another – from an engineering resins producer with big interest supplying the auto industry. During their conference call a few days ago, they cited shortages of nylon and one other product PBT. That was disrupting the supply of engineering resins to their customers. Now, I know there are several types of nylon that might be used in engineering resins. They are a mix; it's not just nylon typically. But from your perspective, is that an isolated incident? Is that something you are seeing in that part of your business, in other words maybe just some color, if you can share it on how that aspect of the nylon market might be supply-demand-wise relative to the broader market? Thank you.

Yes, sure. In auto, you have significant demand for Nylon 6-6 as well as Nylon 6. Nylon 6-6 has had some significant supply shortages happening right now with it. Certainly, there were implications of the storm here for several players. There is a rather significant force majeure happening in Europe right now as it pertains to some key raw materials into that value chain with a number of players out announcing sort of indefinite force majeure. That has certainly crimped the supply side in a key nylon resin for that space. I think, what we saw here in North America was, again, a bit transitory with tropical storm's impact. We did see and continue to see engineering plastics growth for our portfolio, an area of focus for us as we think about that application rate. So, I think there are a number of factors, mostly all supply-side driven as you likely noted. I would say it’s equally, if not more impacted by PA 66 as it is the six at this time.

Yes, no, thank you. I kind of suspected that, but I didn't want to make an assumption. So thank you.

You're welcome.

And then maybe just last one very quickly, but I'm used to reading line charts, and when a line goes up, like someone, I don't know, I don't want to say anything. But someone has a medical condition and a line spikes up on a medical piece of diagnostic equipment that kind of reminds me of what's happening to the asset's price chart that you have been providing quarter after quarter. From your perspective internally, I mean, I'm sure you are enjoying very robust pricing and margins right now on that part. But for planning purposes, how persistent or what duration do you think these elevated spot market or small buyer acetone prices can continue on, on this trajectory Reef and remain at this level? Thanks.

Over the last couple of months here, David, certainly, there is the supply side consideration, but there's also been a significant input cost consideration that has played through the market and influenced underlying pricing as well. On the raw material side, we have seen propylene ease off, right, as one consideration. Relative to underlying supply availability, as I noted, materials have started to flow back as acetone availability throughout the world has improved. We need, let's call it, 10,000 to 15,000 tons give or take to help balance out the market on a monthly basis about 12 came in this month. So again, we're going to see that continuing to trend as phenol utilization globally rebounds. As you may recall, sort of that phenol and nylon recovery with something we were looking at, from the impacts of COVID, those were certainly hit hard. I think as we look to the back half of the year, certainly those are mileposts that we're watching. Phenol demand is improving, an underlying trend for a number of its applications. As supply availability eases, we would expect the moderation as you point out in any cycle here.

Okay, great. Thanks. That's it for me. I appreciate it.

Thank you.

Thanks for all the good questions. This concludes our question-and-answer session. I would like to turn the conference back over to Erin Kane for any closing remarks. Great. Thank you all again for your time and interest this morning. In the current set of industry conditions, we are driving the best possible outcomes for our business. We delivered terrific results in the first quarter of the year and are hopeful you share our excitement about the opportunities that lie ahead. We are confident in our ability to create long-term and sustainable shareholder value as we continue to execute our strategies across the portfolio. So with that, we'll look forward to speaking with you again next quarter. Stay safe and be well.